Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 61% Improvement Relative Risk Recovery time 65% HCQ for COVID-19  Guérin et al.  EARLY TREATMENT Is early treatment with HCQ + AZ beneficial for COVID-19? Retrospective 88 patients in France Faster recovery with HCQ + AZ (p=0.0001) c19hcq.org Guérin et al., Asian J. Medicine and H.., May 2020 Favors HCQ Favors control

Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19

Guérin et al., Asian J. Medicine and Health, July 15, 2020, doi:10.9734/ajmah/2020/v18i730224 (date from preprint)
May 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19hcq.org
Mean clinical recovery time reduced from 26 days (SOC) to 9 days, p<0.0001 (HCQ+AZ) or 13 days, p<0.0001 (AZ). No cardiac toxicity. Small retrospective study of 88 patients with case control analysis with matched patients.
risk of death, 61.4% lower, RR 0.39, p = 1.00, treatment 0 of 20 (0.0%), control 1 of 34 (2.9%), NNT 34, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
recovery time, 65.0% lower, relative time 0.35, p < 0.001, treatment 20, control 34.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Guérin et al., 31 May 2020, retrospective, France, peer-reviewed, 8 authors, dosage 600mg days 1-10, 7-10 days, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary.
This PaperHCQAll
Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19
Violaine Guérin, Pierre Lévy, Jean-Louis Thomas, Thierry Lardenois, Philippe Lacrosse, Emmanuel Sarrazin, Natacha Regensberg-De Andreis, Martine Wonner
Asian Journal of Medicine and Health, doi:10.9734/ajmah/2020/v18i730224
Aims: The challenge regarding COVID-19 is to prevent complications and fatal evolution. Azithromycin (AZM) and hydroxychloroquine (HCQ) have proven their antiviral effect in vitro. We aimed to assess the efficacy and safety of AZM alone or combined to HCQ, prescribed, at an early stage, in patients with Covid-19, in a primary care setting. Study Design: Retrospective observational study. Place and Duration of Study: Patients have been followed by private practitioners in France, between March and April 2020. Methodology: Eighty-eight patients received either no or a symptomatic treatment (NST) (n=34) or AZM alone (n=34) or AZM+HCQ (n=20). The efficacy end point was the time to clinical recovery
Authors' contributions This work was carried out in collaboration among all authors. Authors VG and JLT designed the study and wrote the first draft of the manuscript. Authors VG, TL, ES, NRA, P. Lacrosse and MW followed the patients. Author P. Lévy performed the statistical analysis. All authors read and approved the final manuscript. ETHICAL APPROVAL It is not applicable. COMPETING INTERESTS Authors have declared that no competing interests exist.
References
Agrawal, Goel, Gupta, Emerging prophylaxis strategies against COVID-19, Monaldi Archives for Chest Disease, doi:10.4081/monaldi.2020.1289
Arshad, Kilgore, Chaudhry, Jacobsen, Wang et al., Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis, doi:10.1016/j.ijid.2020.06.099
Barbosa, Da Silva, Costa, Castro, Razuk-Filho et al., Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed by telemedicine
Chen, Hu, Zhang, Jiang, Han et al., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, Med Rxiv, doi:10.1101/2020.03.22.20040758
Fox, Mechanism of action of hydroxychloroquine as an antirheumatic drug, Semin Arthritis Rheum, doi:10.1016/s0049-0172(10)80012-5
Gao, Tian, Yang, Break through: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.5582/bst.2020.01047
Garcia-Cremades, Solans, Hughes, Ernest, Wallender et al., Optimizing hydroxychloroquine dosing for patients with COVID19: An integrative modeling approach for effective drug repurposing, Clin Pharmacol Ther, doi:10.1002/cpt.1856
Gautret, Lagier, Parola, Hoang, Meddeb et al., Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101663
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Guan, Ni, Hu, Liang, Ou et al., for the China medical treatment expert group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China, New Engl J Med, doi:10.1056/NEJMoa2002032
Keyaerts, Vijgen, Maes, Neyts, Van Ranst, In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine, Biochem Biophys Res Commun, doi:10.1016/j.bbrc.2004.08.085
Kim, Jang, Parl, Kim, Hwang et al., Treatment response to hydroxychloroquine, lopinavirritonavir, and antibiotics for moderate COVID-19: A first report on the pharmacological outcomes from South Korea, Med Rxiv, doi:10.1101/2020.05.13.20094193
Lagier, Million, Gautret, Colson, Giraud-Gatineau, Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/ azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101791
Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov, doi:10.1038/s41421-020-0156-0
Mackenzie, Dose refinement in longterm therapy of rheumatoid arthritis with antimalarials, Am J Med, doi:10.1016/0002-9343(83)91269
Menzel, Akbarshahi, Bjermer, Uller, Azithomycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients, Sci Rep, doi:10.1038/srep28698
Meo, Klonoff, Akram, Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19, Eur Rev Med Pharmacol Sci, doi:10.26355/eurrev_202004_21038
Million, Lagier, Gautret, Colson, Fournier et al., Early treatment of 1061 COVID-19 patients with hydroxychloroquine and azithromycin, Marseille, France, Travel Med Infect Dis, doi:.org/10.1016/j.tmaid.2020.101738
Saleh, Gabriels, Chang, Kim, Mansoor et al., The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection, Circ Arrhythm Electrophysiol, doi:10.1161/CIRCEP.120.008662
Savarino, Trani, Donatelli, Cauda, Cassone, New insights into the antiviral effects of chloroquine, Lancet Infect Dis, doi:10.1016/S1473-3099(06)70361-9
Vincent, Bergeron, Benjannet, Erickson, Rollin et al., Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol J, doi:10.1186/1743-422X-2-69
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Yan, Zou, Sun, Li, Xu et al., Anti-malaria drug chloroquine is highly effective in treating avian Influenza A HRN1 virus infection in a animal model, Cell Res, doi:10.1038/cr.2012.165
Yao, Ye, Zhang, Cui, Huang et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis, doi:10.1093/cid/ciaa237
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit